NCT05726370View on ClinicalTrials.gov

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 20, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

May 20, 2030

Conditions
Head and Neck Squamous Cell CarcinomaHead and Neck CancerResectable Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaSecond Primary Squamous Cell Carcinoma of the Head and Neck
Interventions
DRUG

Pembrolizumab

Immunoglobulin G4 monoclonal antibody, via IV infusion

DRUG

CISPLATIN

Platinum agent, via IV infusion

DRUG

Carboplatin

Platinum agent, via IV infusion

DRUG

Docetaxel

Antineoplastic agent, via IV infusion.

Trial Locations (2)

02215

NOT_YET_RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER